Genmab | GEN - Ebit



Genmab reported DKK432M in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Almirall EUR 43.02M 3.42M Jun/2025
Amarin USD -16755000 707K Mar/2025
Amgen USD 2.26B 1.34B Jun/2025
argenx SE USD 288.02M 149.08M Jun/2025
AstraZeneca USD 3.51B 1.3B Jun/2025
Bayer EUR -36000000 2.95B Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Demant DKK 1.87B 471M Jun/2025
Exelixis USD 215.68M 28.82M Jul/2025
Fresenius Medical Care EUR 431M 15M Jun/2025
Galapagos EUR -57027000 101.68M Jun/2025
Genmab DKK 432M 900.27M Jun/2025
GlaxoSmithKline GBP 2.07B 462M Jun/2025
GN Store Nord DKK 461M 119M Jun/2025
GRIFOLS EUR 331.94M 57.97M Jun/2025
Hikma Pharmaceutical USD 317M 85M Dec/2024
Insmed USD -253876000 5.74M Jun/2025
Lonza CHF 727M 193M Dec/2024
Merck EUR 1.03B 26M Jun/2025
Novartis USD -9190000000 13.87B Jun/2025
Regeneron Pharmaceuticals USD 1.52B 608.6M Jun/2025
Roche Holding CHF 11.29B 2.68B Jun/2024
Sanofi EUR 1.51B 1.39B Jun/2025
UCB EUR 502M 168M Dec/2024